Medarex, Inc.
Biopharma company expecting milestone payment from Bristol-Myers Squibb for cancer drug
Published in Elder Law Weekly, December 21st, 2005
The antibody product was developed using Medarex's UltiMAb technology and is the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. Medarex also expects to receive additional milestone payments as well as royalties on any commercial sales resulting from the development of this product.
Medarex is a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Elder Law Weekly
Source: Elder Law Weekly (2005-12-21)
More Articles from Elder Law Weekly
- Hopital Edouard Herriot, Lyon
Bone loss rate significantly increases fracture risk in postmenopausal women - Protein Polymer Technologies, Inc.
Biotech company announces intention to merge with Thuris Corporation - Roskamp Institute, Sarasota
CD40 ligation in microglia perturbs genes associated with amyloid protein - Taipei Veterans General Hospital
Adenosine receptor polymorphism is not linked to Parkinson disease and schizophrenia - AEterna Zentaris, Inc.
Patient enrollment completed for Ozarelix phase II trial in benign prostatic hyperplasia - Acambis Inc.
New developments in flavivirus vaccines are reviewed - More from this issue of Elder Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
